Biocon Biologics Integrates Viatris' Biosimilar Business Across 120 Countries

Earlier this year, the integration process unfolded with over 70 emerging markets in July, followed by the North American business in September and the European business in November.

Biocon Biologics, a subsidiary of Biocon Ltd, has completed the integration of Viatris' biosimilar business in approximately 120 countries, surpassing the initial timeline by a year.

The final phase of this extensive integration included over 10 emerging markets. The markets included Japan, Australia, and New Zealand, thereby marking the completion of Biocon Biologics' transformation into a fully integrated 'lab to market' biosimilar company.

Commenting on the same, Susheel Umesh, chief commercial officer - Emerging Markets, Biocon Biologics, said, “This presents a unique opportunity for our teams to take Brand Biocon Biologics directly to many markets. This self-led business model in key Emerging Markets will take us closer to patients, MoHs, prescribers, and payers. It will allow us to expand affordable access to larger patient pools in these Emerging Markets, thus enabling equitable access to high-quality biosimilars.”

Earlier this year, the integration process unfolded with over 70 emerging markets in July, followed by the North American business in September and the European business in November.

Biocon Biologics claims to boast a commercial presence in around 120 countries, with direct operations in the United States, Canada, Europe, and nine key emerging market countries. These include: India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines.

Further, all biosimilar brands acquired from Viatris, including Ogivri & Hertraz (bTrastuzumab), Abevmy (bBevacizumab), Fulphila (bPegfilgrastim), Hulio (bAdalimumab), Nepexto (bEtanercept), Semglee (bGlargine), and Kirsty (bAspart), will now be marketed by Biocon Biologics teams.

The company claims to address insulin inequity in many emerging markets through its affordable and high-quality biosimilar insulins. Recombinant human insulin and insulin glargine hold a dominant market share in countries including Mexico, Malaysia, Dominican Republic, Malawi, Tanzania, and Mozambique.

In related developments, Eris Lifesciences, based in Ahmedabad, has acquired Biocon Biologics' dermatology and nephrology branded formulations business units in India for INR 366 Cr, with partial funding through debt financing.

The acquisition includes working capital and a team of over 120 professionals from Biocon Biologics' nephro and derma units, set to conclude by the end of November 2023.